Autoimmunity Presentations at American Thyroid Association: 89th Annual Meeting

By October 31, 2019 November 9th, 2019 2019 News Releases, 89th Annual Meeting News, News Releases

The American Thyroid Association will hold its 89th Annual Meeting on October 30-November 3, 2019, at the Sheraton Grand Chicago in Chicago, Illinois. In addition to hearing major speeches and awards, attendees can view the following poster and oral presentations on autoimmunity.

  1. Dr. Mingyan Tian, of The Second Affiliated Hospital of Chongqing Medical University in Chongqing, China, will present a poster, “Pregnancy Outcomes and Proteomic Analysis of IVF Follicular Fluid from Euthyroid Women with Thyroid Autoimmunity” (Poster 54), on Thursday, October 31, 2019. Tian and colleagues assessed the rates of clinical pregnancies, abortions, and live births and used proteomics to measure protein expression in follicular fluid collected from 112 women (49 with thyroid autoimmunity and 63 controls) treated for infertility at The Second Affiliated Hospital. Clinical pregnancy rates were lower and miscarriage rates higher among women with thyroid autoimmunity, compared with controls. Tian and colleagues identified six proteins that were expressed differently in the follicular fluid from women with thyroid autoimmunity, compared with that from controls. This is the first study to use proteomics to explore the relationship between thyroid autoimmunity and lower success rates with in vitro fertilization or intracytoplasmic sperm injection.
  2. Dr. George J. Kahaly, of Johannes Gutenberg University Medical Center in Mainz, Germany, will present the pooled results of phase 2 and phase 3 clinical trials assessing teprotumumab as treatment for thyroid eye disease. The trials randomized 171 patients with recent-onset, moderate to severe thyroid eye disease to receive teprotumumab or placebo infusions every 3 weeks, for a total of eight infusions. Pooled results from the studies showed that, compared with placebo, teprotumumab treatment for 24 weeks reduced inflammation, proptosis, and diplopia and therefore improved quality of life for patients with thyroid eye disease. The presentation is titled, “Efficacy of Teprotumumab, and Insulin-like Growth Factor-1 Receptor Antagonist Antibody, in Patients with Active Thyroid Eye Disease: Pooled Results from Two Placebo-Controlled Trials” (Oral 2) and will be given on Thursday, October 31, 2019.
  3. Dr. Megan Kristan, of Georgetown University Hospital, Washington, District of Columbia, will give an oral presentation, “Immunotherapy-associated Thyroid Disorders: Comparison of the Course of Pre-existing Hypothyroidism Compared with De Novo Hypothyroidism” (Oral 25), on Friday, November 1, 2019. Therapy with immune checkpoint inhibitors have revolutionized treatment for many solid tumors, but it is also associated with several immune-related adverse effects, including endocrinopathies. Ms. Kristan and her colleagues conducted a retrospective cohort chart review for 822 patients who had received immunotherapy between 2010 and 2018. Of these patients, 82 had hypothyroidism before initiating immunotherapy and 37 who developed de novo hypothyroidism. Both groups showed changes in thyroid function tests after 6 to 8 weeks of treatment. The results of this review suggest that current American Society of Clinical Oncology (ASCO) recommendations regarding thyroid hormone supplementation is too high and that a more conservative approach is needed for patients developing hypothyroidism while on immunotherapy. Dr. Kristan and her colleagues also make new recommendations for thyroid function screening.

###

The American Thyroid Association® (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community. ATA® is an international professional medical society with over 1,700 members from 70 countries around the world. Celebrating its 96th anniversary, the ATA® delivers its mission — transforming thyroid care through clinical excellence, education, scientific discovery and advocacy in a collaborative community — through several key endeavors:

  • The publication of the highly regarded professional journals Thyroid®, Clinical Thyroidology®, and VideoEndocrinology
  • Annual scientific meetings
  • Biennial clinical and research symposia
  • Research grant programs for young investigators
  • Support of online professional, public, and patient educational programs
  • Development of guidelines for clinical management of thyroid disease and thyroid cancer

 The ATA® promotes thyroid awareness and information through its online Clinical Thyroidology® for the Public (distributed free of charge to over 12,000 patients and public subscribers) and extensive, authoritative explanations of thyroid disease and thyroid cancer in both English and Spanish. The ATA® website www.thyroid.org serves as a bonafide clinical resource for patients and the public who look for reliable information on the Internet.